Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 14/20 | 0.60 |
| ▸ | RAF1 | P04049 | 3/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.56 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282243 | 0.90 | KDR (0.66) | KDRPDGFRABRAFMAPK14TNNI3K | |
| SCHEMBL717223 | 0.89 | KDR (0.78) | KDRPDGFRARAF1BRAF | |
| SCHEMBL10073786 | 0.82 | PDGFRA (0.80) | KDRPDGFRADDR2 | |
| SCHEMBL282288 | 0.80 | RAF1 (0.64) | KDRPDGFRARAF1BRAFMAPK14 | |
| SCHEMBL282139 | 0.79 | RAF1 (0.54) | KDRRAF1BRAFMAPK14TNNI3K | |
| SCHEMBL718279 | 0.78 | DDR2 (0.67) | KDRPDGFRADDR2 | |
| SCHEMBL282287 | 0.77 | RAF1 (0.56) | KDRPDGFRARAF1BRAFMAPK14 | |
| SCHEMBL282705 | 0.77 | KDR (0.61) | KDRPDGFRARAF1BRAF | |
| SCHEMBL282116 | 0.77 | PDGFRA (0.66) | KDRPDGFRA | |
| SCHEMBL7482725 | 0.77 | KDR (0.80) | KDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | claimed |
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | claimed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | KDR 3633/4885PDGFRA 1115/4885RAF1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.